Safety of calcium antagonists in patients with congestire heart failure

Clinical Therapeutics

Volumn 19, Issue SUPPL. A, 1997, Pages 92-113

  Katz, Stuart ^a,b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b Milstein Hospital   (United States)

Author keywords

Calcium antagonists; Congestive heart failure; Mibefradil; Safety

Indexed keywords

AMLODIPINE; BENZOTHIAZEPINE DERIVATIVE; CALCIUM ANTAGONIST; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; MIBEFRADIL; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; NITRENDIPINE; PHENYLALKYLAMINE; VERAPAMIL;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG STRUCTURE; HEART ATRIUM FIBRILLATION; HEMODYNAMICS; HORMONAL REGULATION; HUMAN; INOTROPISM; REVIEW; VASODILATATION;

EID: 0030663245     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80039-2     Document Type: Article

References (57)

1. Packer M. Calcium channel blockers in chronic heart failure: The risks of "physiologically rational" therapy. Circulation. 1990;82:2254-2257.
2. Young J, Weiner D, Yusuf S, et al. Patterns of medication use in patients with heart failure: A report from the Registry of Studies of Left Ventricular Dysfunction (SOLVD). South Med J. 1995;88:514-523.
3. Elkayam U, Shotan A, Mehra A, Ostrzega E. Calcium channel blockers in heart failure. J Am Coll Cardiol. 1993;22(4 Suppl A):139A-144A.
4. Elkayam U, Weber L, Torkan B, et al. Comparison of hemodynamic responses to nifedipine and nitroprusside in severe congestive heart failure. Am J Cardiol. 1984;53:1321-1329.
5. Fifer M, Colucci W, Lorell B, et al. Inotropic, vascular and neuroendocrine effects of nifedipine in heart failure: Comparison with nitroprusside. J Am Coll Cardiol. 1985;5:731-737.
6. Factor S, Minase T, Cho S, et al. Microvascular spasm in the cardiomyopathic Syrian hamster: A preventable cause of focal myocardial necrosis. Circulation. 1982;66:342-354.
7. Parameshwar J, Poole-Wilson P. The role of calcium antagonists in the treatment of chronic heart failure. Eur Heart J. 1993;14:38-44.
8. Henry P. Comparative pharmacology of calcium antagonists: Nifedipine, verapamil and diltiazem. Am J Cardiol. 1980;46:1047-1058.
9. Opie LH. Calcium channel antagonists in the treatment of coronary artery disease: Fundamental pharmacological properties relevant to clinical use. Prog Cardiovasc Dis. 1996;38:273-290.
10. Braunwald E. Mechanism of action of calcium-channel-blocking agents. NEJM. 1982;307:1618-1627.
11. 2+ channel in cardiac tissue. Eur J Pharmacol. 1995;290:155-158.
12. 2+ channels by Ro 40-5967. Circ Res. 1994;75:144-148.
13. 2+ channel blocker with potent vasodilator but weak inotropic action. J Cardiovasc Pharmacol. 1989;13:754-759.
14. Freedman D, Waters D. Second generation dihydropyridine calcium antagonists. Greater vascular selectivity and some unique applications. Drugs. 1987;34: 578-598.
15. Sun J, Triggle D. Calcium channel antagonists: Cardiovascular selectivity of action. J Pharmacol Exp Ther. 1990;274:419-426.
16. Reicher-Reiss H, Barasch E. Calcium antagonists in patients with heart failure: A review. Drugs. 1991;42:343-364.
17. Piepho R. Calcium antagonist use in congestive heart failure: Still a bridge too far? J Clin Pharmacol. 1995;35:443-453.
18. Elkayam U, Weber L, McKay C, Rahimtoola S. Spectrum of acute hemodynamic effects of nifedipine in severe congestive heart failure. Am J Cardiol. 1985;56:560-566.
19. Packer M, Lee W, Medina N, et al. Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction. J Am Coll Cardiol. 1987;9:622-630.
20. Packer M, Kessler P, Lee W. Calcium-channel blockade in the management of severe chronic congestive heart failure: A bridge too far. Circulation. 1987;75(Suppl V):V56-V64.
21. Packer M. Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure. Circulation. 1989;80(Suppl IV):IV59-IV67.
22. Barjon J, Rouleau J-L, Bichet D, et al. Chronic renal and neurohormonal effects of the calcium entry blocker nisoldipine in patients with severe left ventricular dysfunction. J Am Coll Cardiol. 1987;9:622-630.
23. Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy of and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation. 1990;82:1954-1961.
24. Packer M, Nicod P, Khandheria B, Costello D. Randomized multi-center double-blind placebo controlled evaluation of amlodipine in patients with mild to moderate heart failure. J Am Coll Cardiol. 1991;17:274A. Abstract.
25. Dunselman P, van der Mark T, Kuntze C, et al. Different results in cardiopulmonary exercise tests after long-term treatment with felodipine and enalapril in patients with congestive heart failure due to ischaemic heart disease. Eur Heart J. 1990;11:200-206.
26. de Vries R, Queré M, Lok D, et al. Comparison of effects on peak oxygen consumption, quality of life, and neurohormones of felodipine and enalapril in patients with congestive heart failure. Am J Cardiol. 1995;76:1253-1258.
27. Tan L, Murray R, Littler W. Felodipine in patients with chronic heart failure: Discrepant hemodynamic and clinical effects. Br Heart J. 1987;58:122-128.
28. Littler W, Sheridan D. Placebo controlled trial of felodipine in patients with mild to moderate heart failure. Br Heart J. 1995;73:428-433.
29. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. NEJM. 1988;319:385-392.
30. Goldstein R, Boccuzzi S, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation. 1991;83:52-60.
31. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol. 1990;66:779-785.
32. Israeli SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT): A randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J. 1988;9:354-364.
33. Figulla H, Gietzen F, Zeymer U, et al. Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy: Results of the Diltiazem in Dilated Cardiomyopathy trial. Circulation. 1996;94:346-352.
34. Packer M, O'Connor C, Ghali J, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. NEJM. 1996;335:1107-1114.
35. Cohn J, Ziesche S, Loss L, Anderson G. Effect of felodipine on short-term exercise and neurohormone and long-term mortality in heart rate: Results of V-HeFT III. Circulation. 1995;92:I-143. Abstract.
36. Heywood J, Graham B, Marais G, Jutzy K. Effects of intravenous diltiazem on rapid atrial fibrillation accompanied by congestive heart failure. Am J Cardiol. 1991;67:1150-1152.
37. Goldenberg I, Lewis W, Dias V, et al. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure. Am J Cardiol. 1994;74:884-889.
38. Stauffer J-C, Gaasch W. Recognition and treatment of left ventricular diastolic dysfunction. Prog Cardiovasc Dis. 1990;32:319-332.
39. Nordlander M, Abrahamsson T, Akerblom B, Thalen P. Vascular versus myocardial selectivity of dihydropyridine calcium antagonists as studied in vivo and in vitro. Pharmacol Toxicol. 1995;76:56-62.
40. Foult J-M, Tavolaro O, Anthony I, Nitenberg A. Direct myocardial and coronary effects of enalaprilat in patients with dilated cardiomyopathy: Assessment by a bilateral intracoronary infusion technique. Circulation. 1988;77:337-344.
41. Gibbons G, Dzau V. The emerging concept of vascular remodeling. NEJM. 1994; 330:1431-1438.
42. Pollman M, Yamada T, Horiuchi M, Gibbons G. Vasoactive substances regulate vascular smooth muscle cell apoptosis: Countervailing influences of nitric oxide and angiotensin II. Circ Res. 1996;79: 748-756.
43. Mancini D, LeJemtel T, Factor S, Sonnenblick E. Central and peripheral components of cardiac failure. Am J Med. 1986;80:2-13.
44. Naftilan A, Oparil S. The role of calcium in the control of renin release. Hypertension. 1982;4:670-675.
45. Elkayam U, Roth A, Hsueh W, et al. Neurohumoral consequences of vasodilator therapy with hydralazine and nifedipine in severe congestive heart failure. Am Heart J. 1986;111:1130-1138.
46. Gheorghiade M, Hall V, Goldberg A, et al. Long-term clinical and neurohormonal effects of nicardipine in patients with severe heart failure on maintenance therapy with angiotensin converting enzyme inhibitors. J Am Coll Cardiol. 1991;17:274A. Abstract.
47. Katz A. Calcium channel diversity in the cardiovascular system. J Am Coll Cardiol. 1996;28:522-529.
48. Xu X, Best P. Increase in T-type calcium current in atrial myocytes from adult rats with growth hormone-secreting tumors. Proc Natl Acad Sci USA. 1990;87:4655-4659.
49. 2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res. 1993;73:777-782.
50. Schmitt R, Kleinbloesem C, Belz G, et al. Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther. 1992;52:314-323.
51. Su J, Renaud N, Carayon A, et al. Effects of the calcium channel blockers, diltiazem and Ro 40-5967, on systemic haemodynamics and plasma noradrenaline levels in conscious dogs with pacing-induced heart failure. Br J Pharmacol. 1994;13:395-402.
52. Véniant M, Clozel J-P, Hess P, Wolfgang R. Ro 40-5967, in contrast to diltiazem, does not reduce left ventricular contractility in rats with chronic myocardial infarction. J Cardiovasc Pharmacol. 1991;17:277-284.
53. Ezzaher A, Bouanani N, Su J, et al. Increased negative inotropic effect of calcium channel blockers in hypertrophied and failing rabbit heart. J Pharmacol Exp Ther. 1991;257:466-471.
54. Gray G, Clozel M, Clozel J-P, Baumgartner H-R. Effects of calcium channel blockade on the aortic intima in spontaneously hypertensive rats. Hypertension. 1993;22:569-576.
55. 2+ antagonist Ro 40-5967 on endothelium-dependent responses of isolated arteries. J Cardiovasc Pharmacol. 1994;23:869-876.
56. van der Vring J, Bernink P, van der Wall E, et al. Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure. Clin Ther. 1996;18:1191-1206.
57. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. NEJM. 1991;325:293-302.